US and China Reach Agreement to Slash Tariffs and Cut Drug Prices

Strategic Insights -

The US and China announced a surprise agreement to slash reciprocal tariffs by 115% and pause mutual tariffs for 90 days. This breakthrough comes as President Trump also announced plans to slash generic drug prices, a move contested by pharma companies. The agreement will reduce US tariffs on China from 145% to 30% and Chinese tariffs on the US from 125% to 10%.

Key Takeaways:

  • The US and China agreed to slash reciprocal tariffs by 115%, reducing US tariffs on China from 145% to 30% and Chinese tariffs on the US from 125% to 10%.
  • The agreement will be in place for 90 days, allowing both countries to continue negotiations on economic and trade relations.
  • US Treasury Secretary Scott Bessent characterized the talks as "very productive" and expressed a shared interest between the US and China in balanced trade.
  • Pharam stocks dipped amid President Trump's announcement to slash prescription drug prices by 30% to 80%.
  • The US currently pays two to three times more for the same drugs compared to other wealthy nations.
  • A preliminary step in reducing the gap was taken by the Inflation Reduction Act, which allowed the government to negotiate the price of its most expensive drugs.
  • The order will likely impact pharma markets worldwide, especially India, which is home to the largest number of generic medicine providers.
  • Pharmaceutical companies are opposed to this measure, citing fears that it would cut into their profits and reduce funds for research on new medicines.

Statistics:

  • US tariffs on China will be reduced from 145% to 30%.
  • Chinese tariffs on the US will be reduced from 125% to 10%.
  • The agreement will be in place for 90 days.
  • The US pays two to three times more for the same drugs compared to other wealthy nations.
  • Taiwan's India pharma export rose 16% to about $9 billion last fiscal year.
  • Indian pharmaceutical sector serves 40% of the generic drug demand in the US and 25% of all medicines in the UK.

Sources:

  • Scott Bessent, US Treasury Secretary
  • Jamieson Greer, US Trade Representative
  • Reuters reporting
  • IE Online Media Services Pvt. Ltd., distributed by Contify.com
  • The Wall Street Journal reporting
  • Pharmexcil
  • The Indian Brand Equity Foundation